相关实验视频

Updated: May 26, 2025

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

在患有系统性硬化症相关的间歇性肺病的患者中继续使用宁泰达尼布:来自SENSCIS-ON的3年数据

Yannick Allanore¹, Madelon C Vonk², Oliver Distler³

¹Department of Rheumatology A, Université Paris Cité, APHP, Cochin Hospital, Paris, France yannick.allanore@aphp.fr.

|February 23, 2025

概括

在148周的时间内,丁丁达尼布显示出一致的安全性,并减缓了硬化皮质相关的间歇性肺病 (SSc-ILD) 患者的肺功能下降. 持续的宁泰达尼布治疗对强迫生命能力 (FVC) 产生了持续的影响.

科学领域:

肺部医学肺部医学
类风湿病学类风湿病学
临床药理学临床药理学

背景情况:

结核病相关的间歇性肺病 (SSc-ILD) 是一种进展性疾病,治疗选择有限.
丁丁达尼布是一种氨酸激酶抑制剂,在减缓SSc-ILD肺功能下降方面表现出有效性.
在SENSCIS-ON试验的延期中,评估了宁泰达尼布的长期安全性和有效性.

研究的目的:

在SENSCIS-ON试验中,评估148周内接受开放性忍丹尼布治疗的患者的不良事件和强迫生命能力 (FVC) 的变化.
为了比较在延伸研究期间继续服用宁田尼布的患者和开始服用宁田尼布的患者之间的结果.

主要方法:

从SENSCIS试验中继续服用宁田尼布的患者与在延伸研究中开始服用宁田尼布的患者进行了比较.
记录了不良事件,剂量减少,治疗中断和因不良事件而停止治疗.
分析了148周的FVC与基线的变化.

主要成果:

在这两组中,腹是最常见的不良事件.
较高的剂量减少率,治疗中断率和因不良事件而停止治疗的比率在开始使用宁泰丹尼布的组中观察到.
在第148周,FVC的平均变化在持续组中为-189.1毫升,在开始组中为-126.4毫升,这表明两者都减缓了下降.

结论:

在SENSCIS-ON的148周内,宁泰达尼布的安全概况与之前的研究结果一致.
丁丁达尼布在SSc-ILD患者的肺功能衰退减缓方面表现出持续的影响.
尽管接受了治疗,SSc-ILD的持续进展被观察到,突出显示了持续管理的必要性.

关键词:

结合组织疾病结合组织疾病肺纤维化肺纤维化硬化皮质症,全身性硬化皮质症

更多相关视频

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma

Published on: September 20, 2024

相关概念视频

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...